- Report
- April 2025
- 50 Pages
Global
From €2503EUR$2,650USD£2,130GBP
- Report
- January 2024
- 216 Pages
United States
From €3541EUR$3,750USD£3,014GBP
- Drug Pipelines
- November 2023
- 30 Pages
United States
From €2597EUR$2,750USD£2,210GBP
- Report
- August 2022
- 30 Pages
Global
From €2597EUR$2,750USD£2,210GBP
- Report
- March 2022
- 324 Pages
Global
From €8972EUR$9,500USD£7,635GBP
- Report
- February 2024
- 86 Pages
Global
From €3500EUR$3,970USD£3,083GBP
- Report
- November 2021
- 600 Pages
Global
From €3778EUR$4,000USD£3,215GBP
Sufentanil is an analgesic drug used to treat moderate to severe pain. It is a synthetic opioid, similar to fentanyl, and is administered intravenously or intramuscularly. It is often used in the operating room for general anesthesia and in the intensive care unit for pain management. It is also used in the emergency department for pain relief in trauma patients. Sufentanil is a powerful opioid, and its use is associated with a risk of addiction, abuse, and misuse.
Sufentanil is available in a variety of formulations, including tablets, capsules, and injectable solutions. It is also available in combination with other analgesics, such as acetaminophen and ibuprofen. Sufentanil is typically prescribed for short-term use, and its effects can last up to four hours.
The Sufentanil market is highly competitive, with many companies offering different formulations and combinations of the drug. Some of the major players in the market include Mylan, Pfizer, Teva Pharmaceuticals, and Endo Pharmaceuticals. Show Less Read more